Argus
•
Apr 29, 2026
HALO: Lowering target price to $70.00
Summary
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commerciali
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
Analyst Report: Alnylam Pharmaceuticals, Inc.
May 01, 2026
•
ALNY
Analyst Report: Ionis Pharmaceuticals, Inc.
Apr 30, 2026
•
IONS
Analyst Report: Eli Lilly and Company
Apr 30, 2026
•
LLY
Analyst Report: Ionis Pharmaceuticals, Inc.
Apr 30, 2026
•
IONS
Analyst Report: Incyte Corp
Apr 30, 2026
•
INCY
